(Q43564923)

24 November 2017

Plasma homovanillic acid in untreated schizophrenia--relationship with symptomatology and sex. (English)

1 reference

24 November 2017

1 reference

5

1 reference

24 November 2017

Zhang ZJ

1

1 reference

24 November 2017

Peet M

series ordinal

2

1 reference

24 November 2017

Ramchand CN

series ordinal

3

1 reference

24 November 2017

Shah S

series ordinal

4

1 reference

24 November 2017

1 January 2001

1 reference

Journal of Psychiatric Research

24 November 2017

1 reference

24 November 2017

35

1 reference

24 November 2017

1

1 reference

24 November 2017

23-28

1 reference

Assessment of the Central Dopaminergic Index of Plasma HVA in Schizophrenia

24 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900008-5

Negative v positive schizophrenia. Definition and validation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900008-5

Ventricular enlargement in schizophrenia evaluated with computed tomographic scanning. Effects of gender, age, and stage of illness.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900008-5

3,4-Dihydroxyphenylacetic acid and homovanillic acid in rat plasma: Possible indicators of central dopaminergic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900008-5

The heterogeneity of the long-term course of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900008-5

The negative symptom challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900008-5

Control of exogenous factors affecting plasma homovanillic acid concentration.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900008-5

A comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900008-5

Dopamine in schizophrenia: a review and reconceptualization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900008-5

Schizophrenia throughout life: sex differences in severity and profile of symptoms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900008-5

The effects of diet and physical activity on plasma homovanillic acid in normal human subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900008-5

Origins and significance of dopa and catecholamine metabolites in body fluids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900008-5

Plasma homovanillic acid levels in first-episode schizophrenia. Psychopathology and treatment response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900008-5

3H-spiperone binding sites in post-mortem brains from schizophrenic patients: Relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900008-5

Differential effects of haloperidol on negative symptoms in drug-naive schizophrenic patients: effects on plasma homovanillic acid.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900008-5

Studies of catecholamine metabolism in schizophrenia/psychosis--I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900008-5

Acute effects of neuroleptics on unmedicated schizophrenic patients and controls.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900008-5

Schizophrenic patients with deficit syndrome have higher plasma homovanillic acid concentrations and ventricular enlargement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900008-5

Acute stimulatory effect of estradiol on striatal dopamine synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900008-5

Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900008-5

Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900008-5

Beyond the dopamine hypothesis. The neurochemical pathology of schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900008-5

A comparison of plasma homovanillic acid in the deficit and nondeficit subtypes of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900008-5

Pretreatment plasma homovanillic acid in schizophrenia and schizoaffective disorder: the influence of demographic variables and the inpatient drug-free period

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900008-5

Plasma homovanillic acid as an index of brain dopamine metabolism: enhancement with debrisoquin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900008-5

Sex differences in plasma homovanillic acid levels in schizophrenia and normal controls: relation to neuroleptic resistance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900008-5

Plasma homovanillic acid, plasma anti-D1 and -D2 dopamine-receptor activity, and negative symptoms in chronically mediated schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900008-5

Studies on concentrations of NA and HVA and activity of DBH in the serum from schizophrenic patients, first-degree relatives and normal subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900008-5

Neurotransmitter systems in schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900008-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0022-3956(01)00008-5

1 reference

24 November 2017

1 reference